Prudential Financial’s Soleno Therapeutics SLNO Stock Holding History

Prudential Financial’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,845	Closed	-$765K	–	2579
2026 Q1	$765K	Sell	22,845 -2,010	-8%	-$78.8K	﹤0.01%	1688
2025 Q4	$1.15M	Buy	24,855 +12,695	+104%	+$696K	﹤0.01%	1553
2025 Q3	$822K	Buy	12,160 +7,230	+147%	+$536K	﹤0.01%	1727
2025 Q2	$413K	Buy	+4,930	New	+$369K	﹤0.01%	1996
2021 Q2	–	Sell	-1,034	Closed	-$20K	–	2618
2021 Q1	$20K	Buy	1,034 +107	+12%	+$3.45K	﹤0.01%	2480
2020 Q4	$27K	Hold	927	–	–	﹤0.01%	2428
2020 Q3	$35K	Buy	+927	New	+$27.1K	﹤0.01%	2401

Prudential Financial's SLNO Position: Q2 2026 in Review

Prudential Financial sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 22,845 shares — an estimated $765K sold.

Prudential Financial first reported a position in SLNO in Q3 2020 and held it in 7 quarters. The position peaked at $1.15M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

Prudential Financial reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
Prudential Financial sold 22,845 Soleno Therapeutics shares in Q2 2026, an estimated $765K.
Prudential Financial first reported a position in Soleno Therapeutics in Q3 2020 and held it in 7 quarters.
Prudential Financial's Soleno Therapeutics position peaked at $1.15M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on Prudential Financial's 13F filing for Q2 2026, filed 12 Aug 2026.